The AstraZeneca vaccine may be related to thrombosis but is still recommended to be vaccinated. The neutralizing effect of the inactivated vaccine on the mutant strain is released | The new crown research progress in a week

AstraZeneca vaccine may be linked to rare blood clots, but vaccination is still recommended

AstraZeneca vaccine may be linked to rare blood clots, but it is still recommended to vaccinate AstraZeneca vaccine may be linked to rare blood clots, but vaccination is still recommended

On April 7, the European Medicines Agency (EMA), the British Medicines Agency (MHRA) and the World Health Organization (WTO) successively issued statements stating that the AstraZeneca vaccine may be associated with rare blood clots.

According to EMA, as of March 31, 20 million doses of the AstraZeneca vaccine had been injected into the human body, 79 people developed thrombosis after the first dose of the vaccine, and 19 of them died.

However, considering the balance of pros and cons, the benefits of this vaccination outweigh the risks, and EMA still recommends vaccination for all age groups.

The immunity brought by the mRNA vaccine is maintained for at least 6 months

Immunity brought by mRNA vaccine is maintained for at least 6 months The immunity brought by mRNA vaccine is maintained for at least 6 months

In the S protein binding test (A), pseudovirus neutralization test (B), and live virus neutralization test (C), the vaccinators have higher antibody activity in the body within half a year after the second dose of vaccination (day 29) Source: NEJM

In the S protein binding test (A), pseudovirus neutralization test (B), and live virus neutralization test (C), the vaccinators have higher antibody activity in the body within half a year after the second dose of vaccination (day 29) Source: NEJM's antibody activity in the S protein binding test (A), pseudovirus neutralization test (B) and live virus neutralization test (C) within half a year after the second dose of vaccination (day 29) Both higher source: NEJM

Recently, a study recently published by the New England Journal of Medicine (NEJM) showed that long-term follow-up of Moderna's new crown vaccine vaccinators showed that the immunity brought by the vaccine was maintained for at least 6 months.

Model prediction shows that if the antibody decay rate is assumed to be stable over time (exponential decay model), the estimated half-life of the bound antibody is 52 days; if it is assumed that the decay rate decreases with time (power law model, power -law models), the estimated half-life of the bound antibody is 109 days.

Under the two models, the half-lives of neutralizing antibodies against pseudoviruses were estimated to be 69 days and 173 days, and the half-lives of neutralizing antibodies against live viruses were estimated to be 68 days and 202 days, respectively.

Only one dose of the new crown vaccine has a protective effect of only 3%

Only one dose of the new crown vaccine has a protective effect of only 3%.

The study led by the University of Chile found that two weeks after the second dose of the vaccine, the effectiveness of the vaccine to protect vaccinators was 56.

Chile's new crown vaccination is one of the fastest growing countries in South America, mainly using the new crown vaccine of China Kexing.

The latest results of the neutralizing efficacy of inactivated vaccines against mutant virus strains are released

The latest results of the neutralization efficacy of inactivated vaccines against mutant virus strains are released.

Neutralizing titer changes of BBIBP-CorV or CoronaVac vaccinators against different new coronavirus mutant strains.

Neutralizing titer changes of BBIBP-CorV or CoronaVac vaccinated sera against different new coronavirus mutant strains Source: NEJM BBIBP-CorV or CoronaVac vaccinated sera neutralizing titer changes against different new coronavirus mutants.

First of all, the neutralization ability of the wild-type new coronavirus.

Secondly, the experimental results showed that the neutralizing titer of the B.

The neutralizing titer of CoronaVac vaccinators against the B.

9 potential new treatments for COVID-19 have been discovered

9 potential new therapies for COVID-19 have been discovered 9 potential new therapies for COVID-19 have been discovered

Recently, a study in Cell Reports indicated that the team has identified 9 potential new treatments for COVID-19, including 3 (transplant rejection drug cyclosporine, anticancer drug Dak Mitinib and the antibiotic sarinmycin) have been approved by the Food and Drug Administration (FDA) for the treatment of other diseases.

The research team collected a library of 3059 compounds and used CALU-3 respiratory tract-derived cells to test the antiviral compounds identified through human liver cell screening.
Finally, only 9 compounds were active in the new cells.

Polyethylene glycol allergy causes shock in COVID-19 vaccine recipients

Polyethylene glycol allergy causes shock to COVID-19 vaccine recipients Polyethylene glycol allergy causes shock to COVID-19 vaccine recipients

On April 7, a new report on "Clinical & Experimental Allergy" showed that allergy to polyethylene glycol (PEG) is one of the causes of vaccine anaphylactic shock.
In the case of million doses of safe vaccination.

The researchers pointed out that very few people are allergic to PEG, and they provide a guide to identify those at risk.

"Covid-19 vaccine anaphylactic shock and PEG allergy are both rare, so it is important to prove that PEG is the cause in a vaccine anaphylactic shock.
However, it must be emphasized that PEG allergy is rare.
The COVID-19 vaccine It is still safe.
"

The statistical results of local and systemic reactions after mRNA new crown vaccination are released

The statistical results of local and systemic reactions after mRNA new crown vaccination are released.
The statistical results of local and systemic reactions after mRNA new crown vaccination are released.

Data of local and systemic reactions reported 0-7 days after inoculation of mRNA new crown vaccine Source: JAMA

Data source of local and systemic reactions reported 0-7 days after inoculation of mRNA new crown vaccine: Source: JAMA Data of local and systemic reactions reported 0-7 days after inoculation of mRNA new crown vaccine: JAMA

On April 5, the Journal of the American Medical Association (JAMA) recently published an important study that analyzed data on local and systemic reactions reported actively by 3.
64 million people after being vaccinated with the mRNA COVID-19 vaccine.

After the first dose of the vaccine, the most commonly reported local and systemic reactions include: pain at the injection site (67.
8%), fatigue (30.
9%), headache (25.
9%), myalgia (19.
4%), and chills (8.
8%) ), fever (8.
6%) and joint pain (8.
7%).

For the two mRNA vaccines (Pfizer/BioNTech, Moderna), the reactogenicity after the second dose was significantly stronger, especially the incidence of systemic reactions was significantly higher, including injection site pain (72.
3%), fatigue ( 53.
9%), headache (46.
7%), myalgia (44.
0%), chills (31.
3%), fever (29.
5%) and joint pain (25.
6%).

The optimal strategy for the priority arrangement of the new crown vaccine

The optimal strategy for the priority arrangement of the new crown vaccine The optimal strategy for the priority arrangement of the new crown vaccine

Source of the best allocation of vaccines (vertical axis) among demographic groups in each decision period (horizontal axis): PNAS

The source of the best allocation of vaccines between demographic groups (vertical axis) in each decision period (horizontal axis) : PNAS the best vaccines (vertical axis) between demographic groups in each decision period (horizontal axis) Distribution source: PNAS

Recently, a study published in the Journal of the Proceedings of the National Academy of Sciences (PNAS) fully explained the priority of the new crown vaccine and the probability of saving lives.

The study found that young basic workers are prioritized to control transmission and older people are prioritized to directly control mortality, but the optimal policy is very dynamic: each stage is targeted at specific groups, and these groups over time And change.

When the supply of effective vaccines is sufficient and the epidemic is relatively under control, first target basic workers to help reduce overall transmission; but if vaccine supply is limited and the number of cases and deaths surges, directly targeting the elderly and the most vulnerable populations may be a better strategy .

For the first time, changes in the oral microbial composition of patients with new crown

For the first time, changes in the oral microbial composition of patients with new crowns have been found for the first time

Recently, "Gut" (Gut) published a research paper online, which used 16S rRNA MiSeq sequencing and lipidomics technology to analyze the human microbiome and lipidomics of COVID-19 patients and recovered patients.

The study found that compared with healthy controls (HCs), the oral and fecal microbial diversity of confirmed patients (CPs) was significantly reduced.
Compared with HCs, there are fewer butyrate-producing bacteria in oral CPs, and an increase in lipopolysaccharide-producing bacteria.

The classifier based on the 8 best oral microbial markers (7 fecal microbial markers) has good diagnostic efficiency in different cohorts.
Importantly, in the cross-regional cohort, the diagnostic efficiency reached 87.
24%.

Antiparasitic drugs may prevent new coronavirus-induced lung cell fusion

Antiparasitic drugs may prevent lung cell fusion induced by the new coronavirus.
Antiparasitic drugs may prevent lung cell fusion induced by the new coronavirus.

On April 7, a laboratory study published in Nature found that a drug commonly used to treat tapeworm infections may help prevent the formation of atypical fusion cells in the lungs of COVID-19 patients.

The study showed that the parasite drug niclosamide is one of the most effective molecules.
This drug was found to inhibit virus replication in experiments, weaken the calcium oscillations of cells expressing spike protein, inhibit the activity of TMEM16F, and prevent the formation of syncytia induced by spike protein.

The author pointed out that drugs known to inhibit other members of the TMEM16 protein family also performed well in these experiments, or could be further studied for the treatment of COVID-19.

The key protein was discovered, a key step towards new coronary pneumonia drugs and vaccines

Key protein was discovered, a key step toward new coronary pneumonia drugs and vaccines.
Key protein was discovered, a key step toward new coronary pneumonia drugs and vaccines.

Recently, in a study in the Biophysical Journal, researchers have taken an in-depth study of the interaction between a protein and the genetic material of SARS-CoV-2 to move towards new drugs and vaccines for the prevention and treatment of COVID-19.
The key step.

The researchers used a series of biophysical techniques to measure the size and shape changes of N protein and genomic RNA fragments-1,000 nucleotides of a 30,000 nucleotide genome-when combined.
The results of the study showed that when the protein is a full-length dimer-when two copies are connected to each other, the binding force of the protein is much stronger.

Therefore, drugs that block the flexibility of N protein will be a potential way for pharmaceutical researchers.
Another possibility is to destroy any of those protein/RNA complexes that have been shown to have special significance.

Breastfeeding women vaccinated against the new crown can also protect their babies

Breastfeeding women vaccinated against the new crown vaccine, can also protect the baby breastfeeding women vaccinated against the new crown vaccine, can also protect the baby

Recently, a study published in the American Journal of Obstetrics And Gynecology showed that vaccination during breastfeeding not only protects the mother, but also protects the baby for several months.
After being vaccinated with the new crown vaccine, breastfeeding mothers can deliver protective antibodies to their babies through breast milk for at least 80 days.

The study showed that, two weeks after the first injection of the vaccine, the new crown antibody was contained in breast milk, and the antibody has been present during the three-month study.
At the end of the study, antibody levels are still high, so the protection period of the vaccine may be longer.

More than one-third of patients with new crowns have brain problems

More than one-third of patients with new crowns have brain problems, and over one-third of patients with new crowns have brain problems

On April 6, a research paper in The Lancet Psychiatry showed that after studying the health data of more than 236,000 COVID-19 patients, researchers found that: more than 1/3 of COVID-19 cured patients There was a problem with the brain, and he was diagnosed with a neurological or mental illness within six months of the infection.

Researchers found that as many as 33.
62% of patients with new crowns were diagnosed with neurological or psychological diseases within six months of being cured.
12.
84% of them were diagnosed with neurological or psychiatric diseases for the first time.

Among them, 17% of patients were diagnosed with anxiety, and 14% of patients suffered from mood disorders.
In critically ill patients, neurological diseases are not uncommon.
Nearly 7% have strokes and nearly 2% have been diagnosed with dementia.

The researchers also said that if the statistics included inpatients, the proportion of patients with brain problems would rise to 39%.

Leave a message here